The Use of Erythropoietin in Cancer Treatment and Its Correlation with Ovarian Cancer

Abstract

Erythropoietin is produced by the kidneys, which can stimulate the production of red blood cells, and has a better therapeutic and prognostic role in cancer anemia. Ovarian cancer, which originates from ovarian tissue, is one of the malignant tumors of the female reproductive system, with high lethality and not easy to detect. It has been proved that EPO in correlates with the growth of tumor cells, and its receptor EPOR and recombinant human EPO (rhEPO) are expressed in cancer cells. EPO can treat EPO tumors by restoring endothelial erythrocytes and promoting angiogenesis, while rhEPO mainly has a better ameliorative effect on cancer anemia induced by radiotherapy. However, it remains controversial and contradictory whether EPO has a concomitant promoting effect on tumor cells while relieving ischemia. In this article, we will introduce the sources of EPO and EPOR in vivo, analyze the pathways that promote erythropoiesis, and analyze their effects on tumor cells. It will also confirm the correlation between the two by analyzing the EPO content in ovarian cells. The intervention effect of rhEPO analogs on cancer is also briefly described. Since aberrant activation of the JAK/STAT signaling pathway may exist in ovarian cancer patients, in-depth study of such targets may become a new research direction for the treatment of ovarian cancer.